Group alleged bias toward white, Asian-American applicants Pfizer expresses pride in its commitment to diversity Jan 31 (Reuters) - Pfizer (PFE.N), opens new tab has resolved a lawsuit by a ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. Healthcare lease accounting insights: How two organizations ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

AUSTIN (KXAN) — Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its alleged “unlawful misrepresentations concerning the ...

(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

Pfizer PFE-0.49%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.95%decrease; red down pointing triangle for 2.50 billion ...

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time ...

Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert Bourla. The company achieved its 2024 goal of ...